#Janssen Therapeutics

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

The study of a vaccine that is designed to prevent multiple strains of the virus will include 2,600 women in sub-Saharan Africa.

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.

ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.

To answer that question, these 12 transgender leaders drafted a consensus statement for AIDS United.

The combo of Tivicay (dolutegravir) and Edurant (rilpivirine) showed comparable efficacy to three- and four-drug regimens in major trials.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.

The Janssen Therapeutics funding aims to help African Americans living with HIV in the South and in rural areas.

$40M focuses on keeping girls in school in sub-Saharan Africa.